Tirzepatide

Human evidence can mean a controlled clinical study, an observational study, a safety or exposure report, or evidence from a particular finished formulation. Those are different kinds of information.

More extensive human evidence in specific contexts. Human studies and labelled product evidence are available in specific contexts. This is not a ranking of suitability or a guarantee that every product or use has the same evidence.

Preclinical means research in cells, tissues, or animals rather than in people. It can help researchers form a hypothesis, but it cannot establish a human benefit or a complete human safety profile.

Nonclinical studies supported the pharmacology and safety assessment. Rodent thyroid C-cell tumor findings described in labeling have uncertain human relevance.[1]

Preclinical findings do not establish outcomes in people.

Risk information may describe the compound, a finished product, a route, a population, or product-quality concerns. The cited material does not replace a current product label or an individual professional assessment.

This section is about the United States only. Status applies to a product, formulation, route, population, and use—not to a name in the abstract. A status shown here is not a recommendation or a statement about another country.

• Source/status dateMay 6, 2026

  FDA-approved medicine

  Tirzepatide is FDA approved in product-specific contexts, including Zepbound for labeled chronic weight-management and other labeled uses. Approval is product- and indication-specific.

  Specific product form or route is not separately published in this status record.

  Open source context

The date above is the date attached to the published status record or source context. It is not necessarily the original approval date.

These prompts help organise a conversation with a qualified professional. They do not create a treatment recommendation, dose, or protocol.

• EvidenceWhich human evidence applies to the exact product, form, route, and use being discussed?
• What remains uncertainWhat is known, and what remains uncertain for this specific context?
• RisksWhich important warnings, common effects, and product-quality concerns should be discussed?
• U.S. statusWhat does the U.S. status cover, and what does it not cover?

Related means that the profiles share a topic, pathway, product context, or research question. It does not mean that they are equivalent.

• SemaglutideBoth have FDA-approved metabolic and chronic weight-management products.
• RetatrutideBoth engage incretin pathways; retatrutide remains investigational.

PeptideGrid review date: Jul 22, 2026. Sources support the specific sections that cite them. Publication does not imply endorsement, equivalence, or individual suitability.

1. 1

   ZEPBOUND prescribing information

   DailyMed. ZEPBOUND (tirzepatide) prescribing information. Revised May 2026.

   National Library of Medicine / Eli Lilly · Published May 6, 2026 · Accessed Jul 22, 2026 · Prescribing information

   Open source